Viekirax® (ombitasvir, paritaprevir and ritonavir) has been approved by the EMA and has now been added to the web and app versions of the interactions charts. The combination is listed on the charts by its abbreviations – OBV/PTV/r.
It is important to note that the recommendations for Viekirax (OBV/PTV/r) are based on its European SPC and may differ from the current website recommendations for OBV/PTV/r + dasabuvir which are based on the US Prescribing Information for Viekira Pak®. The website recommendations for OBV/PTV/r + dasabuvir will be updated over the next few weeks to include references from the European SPC and where recommendations differ the website will reflect the more cautious option. The printed versions of the charts will then be updated to include OBV/PTV/r and any revisions to OBV/PTV/r + DSV.
